HSR&D Citation Abstract
Search | Search by Center | Search by Source | Keywords in Title
Plazomicin for the treatment of multidrug-resistant bacteraemia in a patient with underlying chronic kidney disease and acute renal failure requiring renal replacement therapy.
Earle W, Bonegio RGB, Smith DB, Branch-Elliman W. Plazomicin for the treatment of multidrug-resistant bacteraemia in a patient with underlying chronic kidney disease and acute renal failure requiring renal replacement therapy. BMJ case reports. 2021 Aug 19; 14(8).
A 75-year-old man presented with shortness of breath and somnolence and was found to have urosepsis. Blood and urine cultures subsequently grew multidrug-resistant (MDR) (Kp) with the New Delhi metallo-ß-lactamase gene. The patient was treated successfully with plazomicin and meropenem/vaborbactam combination therapy. The course was complicated by acute kidney injury temporarily requiring haemodialysis, gastrointestinal bleed requiring multiple transfusions and hospital readmission with blood cultures again positive with MDR Kp. Plazomicin drug levels were persistently high during treatment, suggesting that therapeutic drug monitoring may be needed to safely use this drug in patients with severe renal dysfunction. This case marks the first use of plazomicin for bacteraemia in the literature outside of a clinical trial and demonstrates its safe and effective use in a patient with advanced renal disease, and provides important insights about dosing and therapeutic drug monitoring considerations in this patient population.